Enlivex Therapeutics Ltd. logo

Enlivex Therapeutics Ltd.

ENLV | NASDAQ
Chart Builder DCF Calculator
$1.29
-$0.10 (-7.19%)
At close: Nov 5, 2026, 3:59 PM ET
$1.35
+$0.06 (+4.65%)
After-hours: Nov 5, 2026, 5:16 PM ET
Fiscal Year
Period Ending
FY 2025
Dec 31, 2025
FY 2024
Dec 31, 2024
FY 2023
Dec 31, 2023
FY 2022
Dec 31, 2022
FY 2021
Dec 31, 2021
FY 2020
Dec 31, 2020
Cash & Equivalents
2.01M 3.3M 813K 49.95M 11.2M 5.67M
Short-Term Investments
3.86M 20.2M 26.51M 299K 72.93M 30.03M
Long-Term Investments
374K 531K 308K n/a 3K 89K
Other Long-Term Assets
n/a 10K 179K 412K 482K 8K
Receivables
235K 1.3M 229K 647K 1.09M 1.24M
Inventory
n/a n/a n/a 1.18M n/a n/a
Other Current Assets
1.73B 198K 5.11M -1.18M 113K -72K
Total Current Assets
1.74B 25.99M 33.76M 52.33M 86.44M 38.12M
Property-Plant & Equipment
938K 1.15M 2.58M 14.9M 8.22M 2.14M
Goodwill & Intangibles
582.51M n/a n/a n/a n/a n/a
Total Long-Term Assets
583.82M 1.69M 3.07M 15.31M 8.7M 2.24M
Total Assets
2.33B 27.69M 36.83M 67.64M 95.15M 40.36M
Account Payables
3.81M 811K 827K 1.95M 878K 463K
Deferred Revenue
n/a n/a n/a n/a n/a n/a
Short-Term Debt
n/a n/a n/a 653K n/a n/a
Other Current Liabilities
1.89M 142K 1.57M 2.71M 1.07M 1.17M
Total Current Liabilities
9.02M 3.8M 6.06M 6.61M 4.72M 4.37M
Long-Term Debt
n/a n/a n/a n/a n/a n/a
Other Long-Term Liabilities
n/a n/a n/a n/a n/a n/a
Total Long-Term Liabilities
383.03M 299K 686K 4.19M 5.39M 499K
Total Liabilities
392.05M 4.1M 6.75M 10.8M 10.11M 4.87M
Total Debt
641K 534K 1.03M 4.85M 6.01M 203K
Book Value
1.93B 23.59M 30.08M 56.84M 85.04M 35.49M
Book Value Per Share
9.58K 275.98 388.71 741.61 1.14K 646.72
Common Stock
28.73M 2.69M 2.14M 2.12M 2.11M 1.65M
Retained Earnings
1.11B -127.11M -112.09M -83.03M -51.97M -37.5M
Comprehensive Income
1.1M 1.1M 1.1M 1.1M 1.1M 977K
Shareholders Equity
1.93B 23.59M 30.08M 56.84M 85.04M 35.49M
Total Investments
4.24M 20.73M 26.82M 299K 72.93M 30.03M

© 2026 bestshares.com. All rights reserved.

All data is for informational purposes only. bestshares.com is not a broker, dealer, or registered investment adviser, and nothing on this site is a recommendation to buy or sell any security.